Abstract: The present invention relates to a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one and to certain compounds for use in that process.British Pat. Spec. No. 1,474,377 discloses inter alia that 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl) butan-2-one possesses useful anti-inflammatory activity. A particularly favored process has now been discovered that can be used to produce 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl) butan-2-one in particularly good yield.The present invention provides a process for the preparation of 4-(6.sup.1 -methoxy-2.sup.1 -naphthyl)butan-2-one which process comprises the hydrogenation of a compound of the formula (I): ##STR1## wherein Ar is a 6-methoxy-2-naphthyl group; X and Y are each hydrogen atoms or together represent a second bond between the carbon atoms to which they are attached; and R is a group such that --CO.sub.2 R represents an ester group convertible by hydrogenation to a CO.sub.2 H group.

Abstract: Compounds of the formula (I): ##STR1## wherein: Y is --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or --C.dbd.C-- n is 1 to 5;R.sub.1 is hydrogen, or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains from 1 to 12 carbon atoms;R.sub.2 is hydrogen, C.sub.1-4 alkyl, trifluoromethyl, or phenyl;R.sub.3 is hydroxy or protected hydroxy;R.sub.5 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-6 alkyl, any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or nitro groups; andX is CH.sub.2 andR.sub.4 is C.sub.1-9 alkyl, C.sub.3-8 cycloalkyl-C.sub.1-6 alkyl, phenyl-C.sub.1-6 alkyl or naphthyl-C.sub.1-6 alkyl, any of which groups may have one acyclic carbon-carbon bond interrupted by an oxygen atom; hydrogen, C.sub.3-8 cycloalky, phenyl or naphthyl, any of which phenyl of naphthyl moieties in R.sub.4 may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkoxy or nitro groups; orR.

Abstract: Skin treatment product for greasy or oily skin comprising an unpigmented oil-in-water or water-in-oil emulsion having dispersed therein 3 to 10% by weight of spherical polymer or copolymer particles having an average size of 5 to 15 microns. The polymer or copolymer particles are cross-linked polystyrene, polymethylmethacrylate or polyethylene microspheres. The oil of the emulsion is a volatile organic liquid in the amount of 1 to 30% of the weight of the emulsion and may be a silicone or silicon glycol.

Abstract: Compounds of the formula (I): ##STR1## and salts and esters thereof, wherein R.sub.1 is a hydrogen atom or a lower alkyl, aryl or aralkyl group, R.sub.2 and R.sub.3 are independently hydrogen, aryl, aralkyl, lower alkyl or substituted lower alkyl, or R.sub.3 is joined to R.sub.1 to form a 4-, 5-, or 6- membered ring or is joined to R.sub.2 to form a 5- or 6- membered ring with the proviso that when R.sub.2 is hydrogen, R.sub.1 is not hydrogen and R.sub.1 and R.sub.3 are not joined to form a group of the sub-formula (a) ##STR2## wherein R.sub.4 is a hydrogen atom or a NH.CO.R.sub.5 group wherein R.sub.5 is a lower alkyl, lower alkoxy lower alkyl, aryl, aralkyl, aryloxyalkyl, lower alkoxy or aryloxy group have .beta.-lactamase inhibitory and anti-bacterial properties.

Abstract: Compounds of the formula (III): ##STR1## wherein R.sub.1 is alkyl of up to 3 carbon atoms and R.sub.2 is alkyl of up to 3 carbon atoms optionally joined to R.sub.1 so that R.sub.1 and R.sub.2 and the carbon atom to which they are attached form a spiro-cyclopentyl or spiro-cyclohexyl ring, and wherein the configuration about the .beta.-lactam ring is trans, are useful in the preparation of antibacterial .beta.-lactam compounds.A process for the preparation of the compounds of the formula (III), is also desired.

Abstract: 4-(6-Substituted naphthyl)butan-2-ols,-butan-2-ones,-pentan-2-ols and -pentan-2-ones bearing a fluoro group in the naphthyl ring, and pro-drugs thereof, are anti-inflammatory agents. A typical embodiment is 4-(4-fluoro-6-methoxy-2-naphthyl)-butan-2-one.

Abstract: A class of 2-substituted benzisothiazolones carrying a nitrogen-containing heterocyclic ring are effective in inhibiting platelet aggregation and are therefore of value in the prophylactic and therapeutic treatment of thrombotic diseases.

Abstract: The present invention provides the compound of the formula (II): ##STR1## and salts and esters thereof.

Abstract: A compound of the formula (I): ##STR1## wherein: X is O, S or H;Y is --CH.sub.2 --CH--, --CH.dbd.CH-- or --C.dbd.C--;n is 1 to 7;R.sub.1 is C.sub.1-4 alkyl;R.sub.3 is hydroxy or protected hydroxy;R.sub.4 is C.sub.1-9 alkyl, C.sub.3-8 cycloalkyl or C.sub.3-8 cycloalkyl--C.sub.1-6 alkyl; orR.sub.2 and R.sub.4 taken with the carbon atom to which they are joined represent a C.sub.5-8 cycloalkyl group; andR.sub.5 is hydrogen or C.sub.1-6 alkyl; and salts thereof has useful pharmaceutical activity including bronchodilator activity.

Abstract: A compound of the formula (I): ##STR1## wherein: X is O or S;Y is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--;n is 1 to 5;R.sub.1 is hydrogen or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains from 1 to 12 carbon atoms;R.sub.2 is hydrogen or C.sub.1-4 alkyl;R.sub.3 is hydroxy or protected hydroxy;R.sub.4 is C.sub.1-9 alkyl, C.sub.3-8 cycloalkyl or C.sub.3-8 cycloalkyl-C.sub.1-6 alkyl; orR.sub.2 and R.sub.4 taken with the carbon atom to which they are joined represent a C.sub.5-8 cycloalkyl group; andR.sub.5 is (CH.sub.2).sub.a NR.sub.6 R.sub.7, wherein a is 0 to 3 and R.sub.6 and R.sub.7 are hydrogen, C.sub.1-4 alkyl or phenyl C.sub.1-4 alkyl, or R.sub.6 and R.sub.7 taken with the nitrogen atom to which they are joined represent a 4 to 7 membered heterocyclic ring which may contain as sole further hetero atom one oxygen atom or one optionally C.sub.1-4 alkyl substituted nitrogen atom; allyl or propargyl; (CH.sub.2).sub.b --CO--(CH.sub.2).sub.c --CH.sub.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: It has been found that an antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms and when pure this antibiotic is an extremely potent inhibitor of many .beta.-lactamases. This antibiotic which we designate MM 4550A may be obtained in substantially pure form by the chromatographic purification of the crude antibacterial complex obtained from the culture medium.

Abstract: Compounds of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof wherein the NR.sub.1 R.sub.2 moiety is a 5-, 6-, or 7-membered saturated heterocyclic ring; R.sub.3 is hydrogen, alkyl of 1 to 4 carbon atoms or acyl of 1 to 4 carbon atoms; R.sub.4 is naphthyl or phenyl unsubstituted or substituted by one or two substituents selected from the group consisting of fluorine, chlorine, bromine, methoxyl, benzyloxyl, trifluoromethyl, methyl, cyano, nitro, acetoxyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, acetamide, hydroxyl, methoxycarbonyl, ethoxycarbonyl, carboxamido, sulphonamido, carboxy, trifluoromethylthio, trifluoromethoxyl, methylsulphonyl, trifluomethylsulphonyl and methylthio; R.sub.5 is hydrogen or alkyl of 1 to 4 carbon atoms; R.sub.6 is hydrogen or alkyl of 1 to 4 carbon atoms; X is oxygen and the dotted line represents a single or double bond.

Abstract: This invention relates to pyrimidine derivatives for treating material and bacterical infestions in humans and animals.

Abstract: The compounds of the formula: ##STR1## and salts and esters thereof are useful agents for the treatment of bacterial infections either alone or in combination with a penicillin or cephalosporin derivative.The preceding compounds may be prepared by the hydrogenation of a compound of the formula: ##STR2## wherein R is a hydrogen atom or an acyl group or a salt or ester thereof.

Abstract: Novel re-usable water-insoluble penicillin acylase complexes are provided wherein a penicillin acylase is adsorbed on a water-insoluble polymer or co-polymer of methacrylic acid and cross-linked with a water-soluble aldehyde selected from the group consisting of glutaraldehyde, glyoxal and formaldehyde. The complexes are useful in the production of 6-APA from penicillins G and V.

Abstract: In a screw capped bottle, a protuberance (7) cooperates with a notch (9) in a notch-bearing member (10) so that as the cap is screwed on, the protuberance bears on the notch-bearing member and one or both deforms to accommodate the threading movement until the protuberance snaps into the notch to terminate the movement. When screwing the cap off, there is an initial resistance to movement while the protuberance and/or notch-bearing member deforms. The protuberance then snaps out of the notch and the cap may be removed.

Abstract: The compounds of the formula (II): ##STR1## and salts and esters thereof wherein R is an inert organic group of up to 18 carbon atoms and are able to inhibit the action of various bacterial .beta.-lactamases. Thus when a compound of the formula (II) or its salt or ester is used together with a penicillin or cephalosporin, the effectiveness of that penicillin or cephalosporin can be considerably enhanced. These novel synergysts can be prepared by etherification of an ester of clavulanic acid followed if desired by de-esterification. The novel synergysts also possess antibacterial activity.

Abstract: Sustained release composition comprising a water soluble veterinary medicament dispersed in a sheet of water insoluble polymer, which sheet is of a size and composition such that it is capable of being constrained in a position which allows oral administration and is, in the rumen, capable of moving relative to this position to retain the composition therein.